Universe Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Universe Pharmaceuticals's earnings have been declining at an average annual rate of -53.1%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 4.8% per year.
Key information
-53.1%
Earnings growth rate
-53.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 4.8% |
| Return on equity | -15.6% |
| Net Margin | -19.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Universe Pharmaceuticals INC's (NASDAQ:UPC) Shares Bounce 27% But Its Business Still Trails The Industry
Apr 07
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 27%
Feb 07There's No Escaping Universe Pharmaceuticals INC's (NASDAQ:UPC) Muted Revenues Despite A 54% Share Price Rise
Dec 18Universe pharmaceuticals receives Nasdaq notification regarding minimum bid price deficiency
Jul 19Improved Earnings Required Before Universe Pharmaceuticals INC (NASDAQ:UPC) Shares Find Their Feet
Feb 21We Think That There Are Some Issues For Universe Pharmaceuticals (NASDAQ:UPC) Beyond Its Promising Earnings
Aug 10Revenue & Expenses BreakdownBeta
How Universe Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 32 | -6 | 9 | 5 |
| 30 Jun 23 | 33 | -9 | 12 | 7 |
| 31 Mar 23 | 34 | -11 | 14 | 10 |
| 31 Dec 22 | 37 | -10 | 18 | 9 |
| 30 Sep 22 | 40 | -9 | 22 | 8 |
| 30 Jun 22 | 44 | -1 | 18 | 6 |
| 31 Mar 22 | 48 | 6 | 15 | 5 |
| 31 Dec 21 | 48 | 9 | 11 | 5 |
| 30 Sep 21 | 48 | 11 | 6 | 5 |
| 30 Jun 21 | 43 | 10 | 5 | 3 |
| 31 Mar 21 | 39 | 10 | 4 | 0 |
| 31 Dec 20 | 35 | 9 | 4 | 0 |
| 30 Sep 20 | 31 | 8 | 3 | 1 |
| 30 Jun 20 | 31 | 8 | 3 | 1 |
| 31 Mar 20 | 31 | 9 | 3 | 1 |
| 31 Dec 19 | 32 | 8 | 3 | 1 |
| 30 Sep 19 | 33 | 8 | 3 | 1 |
| 30 Sep 18 | 29 | 8 | 3 | 1 |
Quality Earnings: UPC is currently unprofitable.
Growing Profit Margin: UPC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UPC is unprofitable, and losses have increased over the past 5 years at a rate of 53.1% per year.
Accelerating Growth: Unable to compare UPC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UPC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: UPC has a negative Return on Equity (-15.59%), as it is currently unprofitable.